BTG3 and systemic sclerosis: A recent blood/skin transcriptional and proteomic analysis revealed that different circulating protein markers of fibrosis and different gene expression profiles were displayed by SSc patients positive for ATA or ARA, suggesting that patient stratification according to ANA antibody subtypes may account for different outcomes in clinical trials targeting specific pathogenic mechanisms [27].